Dr. Stephen J. Schuster

Hematology
3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
On Staff At
Offers Telehealth
3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Schuster is a Hematologist in Philadelphia, Pennsylvania. Dr. Schuster is rated as an Experienced provider by MediFind in the treatment of Hemochromatosis. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 217 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Jefferson Medical College
Residency
Pennsylvania Hospital
Specialties
Hematology
Licenses
Internal Medicine in PA
Board Certifications
Medical Oncology, 1989
Hematology, 1986
Internal Medicine, 1984
Fellowships
Thomas Jefferson University Hospital
Pennsylvania Hospital
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Chester County Hospital
Pennsylvania Hospital
Penn Presbyterian Medical Center
Languages Spoken
English
Gender
Male
Awards
Recognized annually in Philadelphia magazine's Top Docs issue from 2010 through 2025

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Abramson Cancer Center Perelman 4th Floor West
3400 Civic Center Boulevard, West Pavilion, 4th Floor, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Schuster has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Burkitt Lymphoma
Langerhans Cell Histiocytosis
Hodgkin Lymphoma
Waldenstrom Macroglobulinemia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drugs: Tisagenlecleucel, Platinum-based immunochemotherapy, high dose chemotherapy
Study Phase: Phase 3
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2025
Intervention Type: Other, Device
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 2
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Enrollment Status: Completed
Publish Date: October 07, 2025
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Biological
Study Phase: Phase 2
A Phase Ib, Multicenter Study to Determine the Safety and Tolerability of Tisagenlecleucel in Combination With Ibrutinib in Adult Patients With Relapsed and/or Refractory Diffuse Large B-cell Lymphoma
A Phase Ib, Multicenter Study to Determine the Safety and Tolerability of Tisagenlecleucel in Combination With Ibrutinib in Adult Patients With Relapsed and/or Refractory Diffuse Large B-cell Lymphoma
Enrollment Status: Terminated
Publish Date: January 31, 2023
Intervention Type: Biological, Drug
Study Drugs: Tisagenlecleucel, Ibrutinib
Study Phase: Phase 1
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Enrollment Status: Completed
Publish Date: August 15, 2022
Intervention Type: Drug, Biological
Study Drugs: Tisagenlecleucel, Pembrolizumab
Study Phase: Phase 1
Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas
Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas
Enrollment Status: Completed
Publish Date: July 22, 2021
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Enrollment Status: Completed
Publish Date: November 27, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

217 Total Publications

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 18, 2025
Similar Doctors
Distinguished in Hemochromatosis
Dr. Sandra F. Schnall
Hematology Oncology | Hematology | Oncology
Distinguished in Hemochromatosis
Dr. Sandra F. Schnall
Hematology Oncology | Hematology | Oncology
825 Old Lancaster Rd, Suite 320, 
Bryn Mawr, PA 
 (8.5 miles away)
610-527-3800
Languages Spoken:
English
See accepted insurances

Sandra Schnall is a Hematologist Oncology specialist and a Hematologist in Bryn Mawr, Pennsylvania. Dr. Schnall is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, Breast Cancer, and Bone Marrow Aspiration.

Distinguished in Hemochromatosis
Dr. John G. Devlin
Hematology Oncology | Hematology
Distinguished in Hemochromatosis
Dr. John G. Devlin
Hematology Oncology | Hematology

Bryn Mawr Medical Specialists Association

825 Old Lancaster Rd, Suite 320, 
Bryn Mawr, PA 
 (8.5 miles away)
610-527-3800
Languages Spoken:
English
See accepted insurances

John Devlin is a Hematologist Oncology specialist and a Hematologist in Bryn Mawr, Pennsylvania. Dr. Devlin is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. His top areas of expertise are Hemochromatosis, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration.

Distinguished in Hemochromatosis
Dr. Zonera A. Ali
Hematology Oncology | Hematology | Oncology
Distinguished in Hemochromatosis
Dr. Zonera A. Ali
Hematology Oncology | Hematology | Oncology

Alliance Cancer Specialists P.C.

1203 Langhorne Newtown Rd, Suite 135, 
Langhorne, PA 
 (22.6 miles away)
215-750-5050
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Zonera Ali is a Hematologist Oncology specialist and a Hematologist in Langhorne, Pennsylvania. Dr. Ali is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Breast Cancer, Angiosarcoma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schuster's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 12 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile